EU to study potential vaccine for Lyme disease: Companies

· Medical Xpress

edited by Alexander Pol

Alexander Pol

Deputy Editor

Meet our editorial team
Behind our editorial process
Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

reputable news agency

proofread

The GIST Add as preferred source

No vaccine currently exists against Lyme disease, which is transmitted by infected ticks.

EU officials have agreed to study an experimental vaccine against Lyme disease, the world's most common tick-borne illness, its developers said Friday.

Pfizer and the French–Swiss firm Valneva say trials have shown 70% efficacy in people 5 and older for a disease that currently has no approved vaccine.

Despite a disappointing trial result earlier this year, the two firms said the European Medicines Agency had accepted their application for approval of the treatment, formally called PF-07307405.

While rarely fatal, Lyme disease can cause rashes and flu-like symptoms in people bitten by an infected tick and, in some cases, neurological problems.

"We believe vaccination has the potential to provide an important new layer of protection against this debilitating disease," Pfizer's chief vaccines officer, Annaliesa Anderson, said in a joint statement.

Research in 2022 estimated that more than 14% of the global population has had the disease, warning that transmission rates could increase as climate change brings longer, drier summers.

Shares in Valneva surged nearly 16% on the news in early trading on the Paris stock exchange Friday.

The EMA's acceptance "represents a major milestone, especially considering that more than 200 million people live in Lyme disease risk areas in Europe," Valneva's chief executive, Thomas Lingelbach, said in the statement.

Key medical concepts

Lyme Disease

Clinical categories

Infectious diseasesCommon illnesses & PreventionClinical pharmacology Who's behind this story?

Alexander Pol

PhD nano-engineering from Delft University. Published researcher and journal reviewer. Brings scientific insight to content standards. Full profile →

© 2026 AFP

Citation: EU to study potential vaccine for Lyme disease: Companies (2026, August 14) retrieved 14 August 2026 from https://medicalxpress.com/news/2026-08-eu-potential-vaccine-lyme-disease.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.